Advertisement
UK markets close in 7 hours 19 minutes

  • FTSE 100

    8,121.91
    +43.05 (+0.53%)
     

  • FTSE 250

    19,754.20
    +152.22 (+0.78%)
     

  • AIM

    755.53
    +2.41 (+0.32%)
     

  • GBP/EUR

    1.1658
    +0.0002 (+0.01%)
     

  • GBP/USD

    1.2518
    +0.0007 (+0.05%)
     

  • Bitcoin GBP

    51,440.11
    +303.11 (+0.59%)
     

  • CMC Crypto 200

    1,388.14
    -8.39 (-0.60%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.96
    +0.39 (+0.47%)
     

  • GOLD FUTURES

    2,358.90
    +16.40 (+0.70%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,670.55
    +386.01 (+2.23%)
     

  • DAX

    18,027.30
    +110.02 (+0.61%)
     

  • CAC 40

    8,043.48
    +26.83 (+0.33%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

AstraZeneca names Genentech's Bohen as chief medical officer

Reuters - UK Focus

LONDON, Aug 24 (Reuters) - British pharmaceutical company AstraZeneca (NYSE: AZN - news) named Sean Bohen as its chief medical officer, in an appointment that it said could help accelerate the development of new oncology and immunology medicines.

AstraZeneca, Britain's second biggest drugmaker behind GSK , has pinned its future on cancer drugs, where it is vying with rivals such as Bristol-Myers Squibb, Merck (Jakarta: 28586808.JK - news) & Co and Roche in the hot area of immunotherapy treatments, which boost the immune system to fight tumours.

Bohen joins AstraZeneca from Genentech, a biotech company that was bought by Roche in 2009. He will report to Pascal Soriot, the chief executive who last year staved off a mega-merger approach from Pfizer (NYSE: PFE - news) .

"(Bohen's) impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines for patients," Soriot said in a statement on Monday. (Reporting by Sarah Young, Editing by Paul Sandle)